Armata Pharmaceuticals, Inc. (ARMP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2620782d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Armata Pharmaceuticals, Inc. 5005 McConnell Ave Los Angeles, California 90066 July 17, 2026 Dear David: This letter agreement (this “ Agreement ”) is intended to confirm our mutual agreement with respect to your continued
How this was made
The 30-second read
Why it matters
The primary market relevance is governance and retention optics. The agreement specifies salary ($371,315 annualized), a target annual performance bonus (50% of base salary), an intended annual equity grant with approximate $300,000 grant-date fair value, and severance of 12 months base salary under defined termination scenarios.
Market read
This is a compensation and officer appointment disclosure with no accompanying financial guidance, deal, or regulatory action in the provided excerpt.
What to watch
The equity grant is described as an intent with no entitlement to specific terms, which reduces the likelihood of a material valuation impact from this filing alone.
Background
The document is an SEC Form 8-K Item 5.02, attaching an employment letter agreement for a Chief Financial Officer role and related compensatory arrangements.
Ticker impact
Armata’s 8-K discloses a CFO employment agreement with base salary, target bonus, and severance terms tied to termination conditions.
Likely minimal, unless investors interpret the severance or equity grant intent as signaling broader restructuring or retention risk.
The filing is an Item 5.02 executive arrangement update (CFO role, pay, bonus eligibility, equity grant intent, and severance mechanics) without any operational or financial guidance changes in the provided text.
Market effects
No clear sector read-across from a single-company executive compensation agreement.
None indicated.
None indicated.
Counterpoint
Investors could overreact to severance and equity grant intent, but the text does not indicate a change in strategy, financing, or clinical/product milestones.
Key entities
- issuerArmata Pharmaceuticals, Inc.
Subject of the 8-K and party to the CFO employment letter agreement.
- executiveChief Financial Officer (named as “David” in the letter)
Appointed to serve as CFO under the employment agreement terms disclosed in Exhibit 10.1.
